All In Biotech

Drug Trial Radar · NCT06624670

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

A Multi-centre, Randomised, Placebo-controlled, Double-blind, Parallel-group Trial to Evaluate Safety and Efficacy of Spesolimab (BI 655130) in Adult Patients With Ulcerative Pyoderma Gangrenosum (PG) Who Require Systemic Therapy

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Feb 5, 2025

Primary completion

Nov 12, 2027

Study completion Aug 19, 2028

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
Collaborators
Boehringer Ingelheim
First posted
Oct 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to find out whether a medicine called spesolimab helps people with pyoderma gangrenosum (PG). The main aim is to see whether spesolimab leads to closure of PG ulcers. This study is open to adults with ulcerative PG with at least 1 ulcer that measures between 5 cm\^2 to 80 cm\^2 in size. This study has 2 parts. In Part 1, participants are put into groups randomly, which means by chance. 1 group gets spesolimab and the other group gets placebo. Placebo infusions look like spesolimab infusions, but do not contain any medicine. Every participant has a 2 in 3 chance of getting spesolimab. For the first 8 weeks, participants also take corticosteroid medicine by mouth. In Part 2, participants are put into groups again. Participants without open ulcers have an equal chance of getting spesolimab or placebo. Participants with open skin ulcers will get spesolimab. In both parts, participants receive spesolimab or placebo as an infusion into a vein every 4 weeks. Participants are in the study for about 1.5 years. During this time, they visit the study site 20 times. At study visits, doctors check the participant's skin for signs of PG. The doctors also regularly check participants' health and take note of any unwanted effects. The results of the groups are compared to see whether the treatment works.

Conditions

  • Pyoderma Gangrenosum

Interventions

  • SpesolimabDrug

    Solution for infusion

  • Placebo matching to spesolimabDrug

    Placebo matching to spesolimab

  • PrednisoneDrug

    Prednisone

  • PrednisoloneDrug

    Prednisolone

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Achievement of complete closure (PGAR-100 (100% pyoderma gangrenosum area reduction)) of the target PG ulcer at any time up to Week 26 and confirmed at the next consecutive visit (at least 2 weeks later)Time frame: Up to Week 28.

Locations

104 sites in 21 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • Medical Dermatology Specialists Phoenix

    Phoenix, Arizona · Recruiting

  • University of California Irvine

    Irvine, California · Recruiting

  • University of Miami

    Miami, Florida · Recruiting

  • University of South Florida

    Tampa, Florida · Recruiting

  • Advanced Medical Research PC

    Sandy Springs, Georgia · Recruiting

  • Ada West Research

    Meridian, Idaho · Recruiting

  • DeNova Research

    Chicago, Illinois · Not yet recruiting

  • Dawes Fretzin Clinical Research Group, LLC-Indianapolis -68995

    Indianapolis, Indiana · Recruiting

  • Tulane University Hospital and Clinic

    New Orleans, Louisiana · Recruiting

  • Brigham and Women's Hospital

    Boston, Massachusetts · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Dermatology & Cosmetic Center PLLC - Flint

    Flint, Michigan · Recruiting

  • University Health Kansas

    Kansas City, Missouri · Not yet recruiting

  • Red River Research Partners - Lee's Summit

    Lee's Summit, Missouri · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Not yet recruiting

  • Dartmouth Hitchcock Clinics Heater Road

    Lebanon, New Hampshire · Recruiting

  • Dermatology at Lake Success

    Lake Success, New York · Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • Red River Research Partners, LLC

    Fargo, North Dakota · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio · Recruiting

  • Oregon Health and Sciences University

    Portland, Oregon · Recruiting

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • Epiphany Dermatology

    Lewisville, Texas · Recruiting

  • University of Utah Health MidValley Dermatology

    Murray, Utah · Recruiting

  • CIPREC

    CABA, Argentina · Completed

  • Hospital Italiano de Buenos Aires

    CABA, Argentina · Completed

  • Instituto de Especialidades de la Salud Rosario

    Rosario, Argentina · Completed

  • Skin and Cancer Foundation

    Darlinghurst, New South Wales, Australia · Recruiting

  • Royal North Shore Hospital-St Leonards-20807

    St Leonards, New South Wales, Australia · Recruiting

  • Westmead Hospital

    Westmead, New South Wales, Australia · Not yet recruiting

  • Alfred Hospital

    Melbourne, Victoria, Australia · Recruiting

  • Medical University of Graz

    Graz, Austria · Recruiting

  • LKH Salzburg University Hospital

    Salzburg, Austria · Recruiting

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • Chronos Pesquisa Clinica

    Brasília, Brazil · Recruiting

  • Faculdade de Medicina do ABC

    Santo André, Brazil · Recruiting

  • Centre de Recherche Saint-Louis

    Québec, Canada · Recruiting

  • Rejuvenation Dermatology Clinic

    Edmonton, Alberta, Canada · Recruiting

Showing 40 of 104 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.